Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline advances, PAD Phase III trial scheduled to launch in 2027

Smart Finance APP has learned that Rezera is a biotechnology company ready for phase III clinical trials, developing oral NLRP3 inhibitors for inflammatory diseases. On Wednesday, the company submitted an IPO application to the U.S. Securities and Exchange Commission (SEC), with a filing showing a proposed fundraising amount of 100 million US dollars (placeholder figure).